Form 4: Inmune Bio Director Juda Granted 150,000 Stock Options

Inmune Bio, Inc. Director Scott Juda was granted 150,000 stock options with an exercise price of $1.48, vesting monthly over three years.

Summary

• Scott Juda, a Director of Inmune Bio, Inc. (INMB), was granted 150,000 stock options.
• The options have an exercise price of $1.48 per share.
• The grant date for these options was December 1, 2025.
• The options will vest pro rata on a monthly basis over three years (1/36 per month).
• Full vesting will occur on the three-year anniversary of the grant date, December 1, 2028.
• The options were granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan.
• The expiration date for these options is November 23, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a neutral to slightly positive event, as it aligns management's interests with shareholders. It is a routine compensation disclosure rather than a performance indicator.

Positives

• The grant of stock options aligns the Director's financial interests with the long-term performance and shareholder value of Inmune Bio, Inc.
• Stock options serve as an incentive for the Director to contribute to the company's growth and success over the vesting period.

Risks

• Potential future dilution of existing shareholders' equity if the options are exercised, increasing the number of outstanding shares.

Future Outlook

The stock option grant provides a long-term incentive for the Director, aligning their future financial interests with the company's performance over the next three years and beyond, until the options' expiration.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize key personnel. This practice aims to align the interests of management and directors with those of shareholders by tying compensation to the company's stock performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive and director compensation packages across various industries, including biotechnology, to incentivize long-term performance.
• The three-year monthly vesting schedule is a common structure designed to retain talent and encourage sustained contributions over time, comparable to practices at companies like Biogen or Amgen for similar roles.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased alignment of the Director's interests with the company's long-term stock performance.
• Director (Scott Juda): Receives a significant equity incentive, aligning personal financial success with the company's growth and stock value.

Next Steps

• The options will continue to vest monthly over the next three years, with full vesting by December 1, 2028.

Key Dates

Keywords

Inmune Bio, INMB, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Incentive Plan, Vesting Schedule